MBX Biosciences, Inc. (MBX)
| Market Cap | 1.95B +548.5% |
| Revenue (ttm) | n/a |
| Net Income | -86.67M |
| EPS | -2.19 |
| Shares Out | 47.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,883,087 |
| Open | 34.94 |
| Previous Close | 34.71 |
| Day's Range | 34.56 - 41.28 |
| 52-Week Range | 9.43 - 44.89 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 56.00 (+36.7%) |
| Earnings Date | May 7, 2026 |
About MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy fo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for MBX stock is "Strong Buy." The 12-month stock price target is $56.0, which is an increase of 36.70% from the latest price.
News
MBX Biosciences reports Q1 EPS (51c), consensus (58c)
“We continue to make excellent progress across our pipeline in 2026, including advancement toward initiation of our Phase 3 trial of once-weekly canvuparatide following a successful End-of-Phase 2 mee...
MBX Biosciences appoints Mark Soued as chief commercial officer.
MBX Biosciences (MBX) announced the appointment of Mark Soued as chief commercial officer. Most recently, Soued served as senior VP, head of U.S. at Alnylam Pharmaceuticals (ALNY). Published first on
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Ma...
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
CARMEL, Ind. and BURLINGTON, Mass.
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
CARMEL, Ind. and BURLINGTON, Mass.
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pr...
MBX Biosciences initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of MBX Biosciences (MBX) with an Outperform rating and $75 price target
Options Volatility and Implied Earnings Moves Today, March 23, 2026
Today, several major companies are expected to report earnings: Bioline RX Ltd Sponsored ADR (BLRX), Lithium Argentina (LAR), MBX Biosciences, Inc. (MBX). Ahead of earnings, TipRanks shows you the exp...
MBX Biosciences files automatic mixed securities shelf
16:09 EDT MBX Biosciences (MBX) files automatic mixed securities shelf
MBX Biosciences reports Q4 EPS (49c), consensus (63c)
“2025 was a year of continued growth and execution for MBX, highlighted by the clinical validation of our Precision Endocrine Peptide platform,” said Kent Hawryluk, President and Chief Executive Offic...
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for o...
MBX Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference
The platform enables extended peptide therapies for endocrine and metabolic diseases, with phase III for once-weekly PTH therapy in hypoparathyroidism starting Q3 and a robust obesity pipeline advancing. Key differentiators include urine calcium endpoints and monthly dosing for obesity, with major data readouts expected in Q2 and Q4.
MBX Biosciences Transcript: The Citizens Life Sciences Conference 2026
FDA alignment for phase three in hypoparathyroidism keeps timelines on track, with strong phase two results and high physician interest in once-weekly dosing. Obesity pipeline advances with MBX 4291 and additional candidates, supported by robust funding into 2029.
MBX Biosciences appoints Basbaum as Chief Business Officer
MBX Biosciences (MBX) announced the appointment of Karen Basbaum, MBA, as Chief Business Officer, CBO. Prior to joining MBX Biosciences, Basbaum served as Senior Vice President of Business Development...
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pr...
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows.
MBX Biosciences ‘on track’ to initiate Phase 3 in Q3 following EOP 2 meeting
MBX Biosciences (MBX) announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration to discuss the overall Phase 3 trial design for once-weekly canvuparat...
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pr...
MBX Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Significant progress was highlighted across endocrine and obesity programs, with phase III trials for canvorparotide set for Q3 and key obesity data expected in Q4. The proprietary PEP platform underpins a robust pipeline, strong financials, and multiple near-term catalysts.
MBX Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026 is set as a transformative year with major clinical milestones, including phase III initiation for canvuparatide and key obesity program readouts. Strong financials support pipeline expansion, with robust physician and patient enthusiasm for once-weekly therapies.
MBX Biosciences to Participate in Upcoming March Investor Conferences
CARMEL, Ind., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel pr...
MBX Biosciences to Participate in Upcoming Investor Conferences
CARMEL, Ind., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel pr...
MBX Biosciences initiated with an Overweight at Barclays
Barclays initiated coverage of MBX Biosciences (MBX) with an Overweight rating and $66 price target Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive
MBX Biosciences appoints Laurie Stelzer to board of directors
MBX Biosciences (MBX) announced the appointment of Laurie Stelzer as an independent director on the Company’s Board of Directors and as chairperson of the board’s audit committee. Stelzer previously s...
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pre...